Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group
Prospective trials are required to clarify the role of ctDNA as a valid surrogate end point for progression-free or overall survival in GI cancers.
Authors
- Daniela Molena (ORCID: https://orcid.org/0000-0003-1655-4473)
- Michael K. Gibson (ORCID: https://orcid.org/0000-0002-1500-9281)
- Anup Kasi (ORCID: https://orcid.org/0000-0002-4305-5701)
- Kelsey A. Klute (ORCID: https://orcid.org/0000-0002-4748-8520)
- Cathy Eng (ORCID: https://orcid.org/0000-0003-2335-0612)
- Van Karlyle Morris (ORCID: https://orcid.org/0000-0002-4911-2252)
- Lakshmi N. Rajdev (ORCID: https://orcid.org/0009-0005-9747-6121)
- Philip A. Philip (ORCID: https://orcid.org/0000-0002-6513-3491)
- Christopher H. Lieu (ORCID: https://orcid.org/0000-0002-4852-4642)
- Arvind N. Dasari (ORCID: https://orcid.org/0000-0001-5271-9744)
- Thomas J. George (ORCID: https://orcid.org/0000-0002-6249-9180)
- Nataliya V. Uboha (ORCID: https://orcid.org/0000-0003-3449-1680)
- Akhil Chawla (ORCID: https://orcid.org/0000-0003-3122-6873)
- Aparna R. Parikh (ORCID: https://orcid.org/0000-0002-5245-7841)
- Mark H. O’Hara (ORCID: https://orcid.org/0000-0003-2751-6122)
- Theodore Sunki Hong (ORCID: https://orcid.org/0000-0001-8481-6581)
- Gregory P. Botta (ORCID: https://orcid.org/0000-0001-9606-4508)
- Dustin A. Deming (ORCID: https://orcid.org/0000-0003-2394-9836)
- Karyn A. Goodman (ORCID: https://orcid.org/0000-0002-4576-6355)
- Midhun Malla (ORCID: https://orcid.org/0000-0002-9969-588X)
- Daniel A. King (ORCID: https://orcid.org/0000-0001-6451-712X)
- Stacey A. Cohen (ORCID: https://orcid.org/0000-0002-6207-9856)
- Salma K. Jabbour (ORCID: https://orcid.org/0000-0001-8200-5371)
- Carmen J. Allegra (ORCID: https://orcid.org/0000-0001-6402-2709)
- Samuel Jacob Klempner (ORCID: https://orcid.org/0000-0002-4062-0808)
- Gentry Teng King (ORCID: https://orcid.org/0000-0002-7525-8802)
- Jennifer R. Eads (ORCID: https://orcid.org/0000-0002-0491-4518)
- Shubham Pant (ORCID: https://orcid.org/0000-0001-9281-480X)
- Manish A. Shah (ORCID: https://orcid.org/0000-0002-6913-9655)
- Andrew M. Lowy (ORCID: https://orcid.org/0000-0002-7106-0735)
- Kristen Spencer (ORCID: https://orcid.org/0000-0001-5577-3439)
Institutions
- Rutgers, The State University of New Jersey (US)
- Northwestern University (US)
- Northwell Health (US)
- Feinstein Institute for Medical Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Wisconsin–Madison (US)
- Harvard University (US)
- Wayne State University (US)
- University of Washington (US)
- Cornell University (US)
- University of Florida Health (US)
- University of Alabama at Birmingham (US)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
- Presbyterian Hospital (US)
- University of Kansas Medical Center (US)
- University of Colorado Cancer Center (US)
- National Cancer Institute (US)
- UF Health Cancer Center
- New York University (US)
- University of Nebraska Medical Center (US)
- University of Pennsylvania (US)
- University of Colorado Denver (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1200/po-24-00489
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- American Society of Clinical Oncology
- FibroGen
- Lantheus Medical Imaging
- Boston Scientific Corporation
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Exelixis
- Jazz Pharmaceuticals
- Cholangiocarcinoma Foundation
- Celldex Therapeutics
- Novocure
- US WorldMeds
- Parker Institute for Cancer Immunotherapy
- Nihon Medi-Physics
- Mersana Therapeutics
- Mirati Therapeutics
- BeiGene
- Incyte
- Syndax Pharmaceuticals
- Cardinal Health
- NGM Biopharmaceuticals
- Revolution Medicines
- Seagen
- Natera
- Eisai
- Astellas Pharma
- European Society for Medical Oncology
- Ipsen
- Bavarian Nordic
- Geistlich Pharma
- Genentech
- EMD Serono
- Foundation Medicine
- Daiichi Sankyo Europe